



MESCO PHARMACEUTICALS LIMITED

Corporate Identity No. L24111UR1986PLC015895

Corp. Office & Correspondence Address:

H-1, Zamrudpur Community Centre, Kailash Colony, New Delhi- 110 048
Tel: 011 29241099, 40587083, E-mail: nsparameswaran@mescosteel.com

To,
The General Manager
Listing Operation,
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

Date: 14.08.2017

Sub : Submission of quarterly financial results of the Company as per Regulation 30 and 33 of the Listing Regulations for the quarter ended on 30th June, 2017

Dear Sir,

This is with regard to Mesco Pharmaceuticals Limited (SCRIP CODE : 500274). Pursuant to the Regulation 30 of the Listing Regulations, we would like to inform you that the Board of Directors of the Company approved the Unaudited financial results for the quarter ended on 30th June, 2017 in a duly convened Board Meeting held on Monday, 14th August, 2017 in manner as prescribed under Regulation 33 of the Listing Regulations and the same was reviewed by the Statutory Auditors of the Company.

The meeting of the Board of Directors of the Company Commenced at 11.30 AM and concluded at 12.45 PM.

Kindly take into your record the above said Quarterly Results along with the Limited Review Report.

Annexure: Limited Review Report and Quarterly Results of the Company for quarter ended on 30th June, 2017

For Mesco Pharmaceuticals Limited

N.S. Parameswaran
N.S. Parameswaran
Managing Director
DIN : 00091097



MESCO PHARMACEUTICALS LTD

CIN : L24111UR1986PLC015895

REGD.OFFICE : UPPER KESALTON, TALLITAL, NAINITAL-263 001, UTTARAKHAND

Tel. :+91-9871862796, W: www.mesopharma.com; E-mail : nsparameswaran@mescosteel.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2017

Sl No	PARTICULARS	Quarter Ended		Year Ended	
		30.06.2017	31.03.2017	30.06.2016	31.03.2017
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	Income from Operations				
	(a) Net Sales/ Income from operations	0.00	0.00	0.00	0.00
	(b) Other Income	0.00	0.00	0.00	0.00
	Total Income from Operations (net)	0.00	0.00	0.00	0.00
2	Expenses				
	(a) Cost of Material Consumed	0.00	0	0.00	0
	(b) Change in Inventories of finished goods and work in progress	0.00	0	0.00	0
	(c) Employees Benefits Expenses	81,387.00	177,500.00	67,968.00	374,505.00
	(d) Depreciation and Amortisation expenses	0.00	0	0.00	0
	(e) Finance Cost	0	0.00	0	0
	(f) Other Expenses	429,118.20	2,164,354.00	7,000.00	2,205,464.00
	Total Expenses	510,505.20	2,341,854.00	74,968.00	2,579,969.00
3	Profit/(Loss) Before Exceptional items and Tax	(510,505.20)	(2,341,854.00)	(74,968.00)	(2,579,969.00)
	Finance Costs & Exceptional Items (1-2)				
	Exceptional Items	0.00	0.00	0.00	0.00
4	Profit/(Loss) before Tax	(510,505.20)	(2,341,854.00)	(74,968.00)	(2,579,969.00)
	(a) Current Tax	-	9,705.00	-	9,705.00
	(b) Deferred Tax	-	-	-	-
	(c) Tax expense relating to Earlier years	-	-	-	-
7	Profit for the Period	(510,505.20)	(2,351,559.00)	(74,968.00)	(2,589,674.00)
	Other Comprehensive Income				
	If any	-	-	-	-
	Total Comprehensive Income for the Period	(510,505.20)	(2,351,559.00)	(74,968.00)	(2,589,674.00)
14	Paid up Equity Share Capital	197,381,000.00	197,381,000.00	197,381,000.00	197,381,000.00
	(Face value Rs.10/- per Equity Share)				
16	Earning per share (before and after extraordinary items) (Rs.10- each)				
	Basic (Rs.)	(0.03)	(0.12)	(0.00)	(0.13)
	Diluted (Rs.)	(0.03)	(0.12)	(0.00)	(0.13)

Notes :

- The above Results, have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective Board Meeting held on 14th August, 2017
- The Statutory Auditors of the Company have carried out Limited Review of the above Results.
- Figures for the previous period have been re-classified, re-grouped/ re-arranged wherever necessary.
- There were no manufacturing activities in the company during the period under consideration
- The Company has adopted Indian Accounting Standards ("Ind AS") from April 1, 2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder. There is no impact of transition to Ind AS, hence reconciliation is not given.



N.S. PARAMESWARAN
MANAGING DIRECTOR
DIN : 00091097

N. Dhawan & Co

CHARTERED ACCOUNTANTS

411, Bhera Enclave, Paschim Vihar, Outer Ring Road, Delhi - 110 087

Call: 011-4234 2154, 93 135 10400, email: mail@ndhco.com

Review Report to MESCO PHARMACEUTICALS LIMITED

We have reviewed the accompanying statement of Unaudited financial results of **MESCO PHARMACEUTICALS LIMITED** for the quarter ended June 30, 2017, being submitted by the company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, read with SEBI circular CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with Indian Accounting Standard ("IND-AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles general accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No: CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N. Dhawan & Co.
Chartered Accountants
Firm Registration No. 007095N


Naresh Dhawan
Proprietor
M. No. 85968



Date: 14th August, 2017
Place: New Delhi